Featuring perspectives from Ms Meetal Dharia, Dr Robert L Ferris, Dr Robert Haddad and Ms Lynsey P Teulings, including the following topics:

• Introduction (0:00)
• The Biology of Head and Neck Cancer (15:41)
• The Multidisciplinary Treatment of Head and Neck Cancer (18:14)
• Ongoing Screening and Prevention After Potentially Curative Therapy for Head and Neck Cancer (33:03)
• Radiation Therapy and Chemotherapy Side Effects (41:02)
• The Potential Short- and Long-Term Effects of Surgery for Head and Neck Cancer (49:50)
• Emerging Treatment Strategies Aimed at Improving Outcomes Associated with Localized or Locally Advanced Head and Neck Cancer (56:46)
• Tolerability Considerations with Xevinapant (1:06:13)
• The Established Role of Anti-PD-1/PD-L1 Antibodies in Therapy for Advanced Head and Neck Cancer (1:17:35)
• Newly Approved Immunotherapeutic Strategies for Nasopharyngeal Carcinoma (1:19:27)
• The Tolerability of Immune Checkpoint Inhibitors (1:24:09)

NCPD information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Adam S Kibel, Dr Laurence Klotz and Dr Sandy Srinivas, moderated by Dr Elisabeth I Heath, including the following topics:

• Introduction (0:00)
• Recent Data Defining the Optimal Use of Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Kibel (2:39)
• Side Effects and Other Practical Considerations with Hormonal Therapy for Nonmetastatic Prostate Cancer — Dr Klotz (27:04)
• Current and Future Approaches to Hormonal Therapy for Metastatic Prostate Cancer — Dr Aggarwal (51:07)
• New Considerations with the Use of PARP Inhibitors for Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Dr Srinivas (1:13:53)
• Other Novel Therapies for Patients with Metastatic Prostate Cancer — Dr Heath (1:38:52)

CME information and select publications

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics:

• Follicular Lymphoma (0:00)
• Mantle Cell Lymphoma (30:29)
• Diffuse Large B-Cell Lymphoma (55:01)
• Hodgkin Lymphoma (1:12:25)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Elias Jabbour, including the following topics:

• Clinical management of Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL); factors in the selection of initial induction  treatment (0:00)
• Primary and secondary endpoint outcomes from the Phase III PhALLCON trial comparing ponatinib to imatinib, each with reduced-intensity chemotherapy, as front-line treatment for Ph-positive ALL (5:22)
• Efficacy and tolerability of ponatinib in combination with blinatumomab for patients with newly diagnosed Ph-positive ALL (17:04)
• Ongoing research with novel agents and strategies for Ph-positive ALL (24:47)

CME information and select publications

Featuring an interview with Dr Elias Jabbour, including the following topics:

• Evolution of research and therapeutic options for acute lymphoblastic leukemia (ALL) (0:00)
• Clinical and biological characteristics of ALL and implications for prognosis and disease management (6:36)
• Case: A 48-year-old woman with newly diagnosed Philadelphia chromosome-positive (Ph-positive) ALL attains complete remission with ponatinib/blinatumomab (14:03)
• Tolerability and improved quality of life with the chemotherapy-free combination of ponatinib and blinatumomab (24:17)
• Case: A 38-year-old man with newly diagnosed Ph-positive ALL experiences a complete molecular response with induction hyper-CVAD and ponatinib (27:10)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Joshua Richter, including the following topics:

• Similarities and differences between the cellular targets and mechanisms of action of BCMA- and non-BCMA-directed bispecific antibodies for multiple myeloma (MM) (0:00)
• Antitumor activity observed with teclistamab and elranatamab for relapsed/refractory MM (3:46)
• Published findings with investigational anti-BCMA bispecific antibodies such as linvoseltamab and alnuctamab for pretreated MM (12:40)
• Efficacy and safety of approved and investigational non-BCMA-targeted bispecific antibodies in patients with heavily pretreated MM (16:26)
• Early data with bispecific antibodies in combination with other systemic therapies for MM (22:55)
• Spectrum, incidence, severity and timing of cytokine release syndrome, neurotoxicity and other adverse events with BCMA- and non-BCMA-targeted bispecific antibodies (26:39)

CME information and select publications

Featuring an interview with Dr Joshua Richter, including the following topics:

• Management of cytokine release syndrome after bispecific antibody therapy; importance of clinical trials in the multiple myeloma (MM) treatment paradigm (0:00)
• Similarities and differences between and efficacy and tolerability of BCMA- and non-BCMA-directed bispecific antibodies in the treatment of MM (7:18)
• Case: A woman in her mid 60s with penta-refractory MM who achieves complete remission with linvoseltamab on a clinical trial (12:53)
• Case: A woman in her early 60s with multiregimen-refractory MM who experiences pain and tumor flare during step-up dosing of teclistamab (22:40)
• Case: A man in his late 60s with relapsed/refractory MM who experiences disease relapse 18 months after chimeric antigen receptor T-cell therapy begins treatment with talquetamab (28:34)
• Racial and ethnic disparities in the treatment of MM (32:09)

CME information and select publications

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics:

• Introduction (0:00)
• Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40)
• Role of Immunotherapy in Intermediate-Stage HCC (17:02)
• First-Line Therapy for Advanced HCC (19:56)
• Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29)
• Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02)
• Potential Role of HER2-Targeted Therapy for BTCs (1:17:16)

CME information and select publications